Quantcast
 
New ETF Book by Larry Connors - Click here to read more


 

Mentor Capital, Inc. Rated a $5/sh Speculative Buy on Immune System Breast Cancer Treatment in FDA Phase I/II Trials

Fri. October 30, 2009; Posted: 07:58 AM
Stocks RSS
SAN DIEGO, Oct 30, 2009 (BUSINESS WIRE) -- MNTR | Quote | Chart | News | PowerRating -- Mentor Capital, Inc. (Pink Sheets: MNTR | Quote | Chart | News | PowerRating) is well poised to be a significant participant in the expanding medical sector of Cancer Immunotherapy with a $5 price objective according to Senior Securities Analyst Howard N. Stillman. That implied 165% gain over the current $1.89/share price, compounds the 88% three-month stock price appreciation already experienced by the Company since it announced its exclusive investment focus on this emerging approach to overcome the historic medical nemesis of cancer.

In any immunotherapy, mild flu-like symptoms are experienced by the patients as compared to the severe side effects experienced after chemotherapy, radiation, or surgical treatments. Mentor Capital's primary investee, Quantum Immunologics, Inc., is conducting FDA authorized Phase I/II trials for its metastatic breast cancer treatment to test the goal of enabling the human immune system to identify and kill breast cancer cells with no harm to other healthy tissue. A 40% selection by late stage breast cancer patients of immunotherapy over chemotherapy projects to $2 Billion in annual revenue. Mentor Capital stepped warrants could raise up to $145 Million to support that commercial introduction of Quantum medical technologies. The Mentor Funding Agreement contemplates "significantly increased investment, or even merger of the parties."

It is interesting to note that the common stock of Dendreon Corporation (DNDN), pursuing a similar technology to treat prostate cancer, has appreciated 1,000% in the past six months of this year. Mr. Stillman concludes, "The MNTR shares at current price levels represent exciting speculative prospects to risk oriented investors seeking material capital gains potential." The entire text of the October 21, 2009 report commissioned by Mentor Capital from Mr. Stillman may be viewed at: http://www.mentorcapital.com/$5-Share-Sr.-Securities-Analyst.html.

Howard N. Stillman has over 20 years of Wall Street experience and served as Director of Research at two New York Stock Exchange firms. There he was approved by the New York Stock Exchange as a Supervisory Analyst and held membership in the New York Society of Security Analysts. Mr. Stillman earned an MBA in Finance from New York University and taught finance and economics at the college level. He has often been called as an expert witness in investment fraud cases and has participated in over 100 such cases since 1987. Mr. Stillman holds no Mentor Capital nor Quantum Immunologics securities.

Forward-Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

SOURCE: Mentor Capital, Inc.

Mentor Capital, Inc. 
Chet Billingsley, CEO 
760-788-4700
For full details for MNTR click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Most Popular News
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.